ArticleCureus2025
Magnetic Resonance Imaging/Transrectal Ultrasound (MRI/TRUS) Fusion-Guided Prostate Biopsy: A Single-Center Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe role of magnetic resonance imaging (MRI) targeted biopsy has increased in the diagnostic pathway of prostate cancer. The objective of this study was to describe our experience with MRI/transrectal ultrasound (MRI/TRUS) fusion-guided prostate biopsy in a regional hospital, with an emphasis on the technique of the procedure. Methods: This was a single-center, retrospective study. Cases of MRI/TRUS fusion-guided prostate biopsy performed in Pamela Youde Nethersole Eastern Hospital, Hong Kong, from September 2022 to December 2024 were reviewed. Systematic biopsy was also performed for all cases. Data were retrieved from electronic medical records. Procedural-related technical factors, fusion success rate, complications, and histopathological results were reviewed.
resultsA total of 125 patients were included in the study, with successful MRI/TRUS fusion performed in 124 patients (99.2%). The median number of passes to each targeted lesion was three (range: two to five). A total of 29 targeted prostate lesions (12.2%, among 28 patients) showed adenocarcinoma. An additional 11 cases of adenocarcinoma were detected in the systematic biopsy cores. The overall per-patient prostate cancer detection rate was 31% (39/124). Post-biopsy complications were observed in 19 patients (15.3%), with acute retention of urine being the most common complication (n=10, 8.1%).
conclusionMRI/TRUS fusion-guided prostate biopsy is a feasible and safe procedure. Our experience with the procedure, including peri-procedure assessment, fusion technique, and biopsy technique, was described in detail. A combination of systematic and MRI/TRUS fusion-guided targeted biopsies of the prostate is recommended as part of the diagnostic pathway in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.